False-Positive Results of Radionuclide Imaging in Lactating Breasts: a pharmacovigilance perspective
Vojislav Kišić1 and Jennifer Parish2
1University of Belgrade School of Medicine, Dr. Subotića 8, 11000 Belgrade, Serbia.
2IQVIA, Leskoškova cesta 2, 1000 Ljubljana, Slovenia.
Received March 2, 2020; Revised March 20, 2020; Accepted April, 2020
Background: Misleading diagnostic results, including false-positives, potentially impact both the safety and efficacy profiles of radiopharmaceuticals used for diagnostic purposes. It is unclear, however, if false-positives occurring with radio-pharmaceuticals in lactating breasts are regularly reported as adverse events.
Methods: Scientific medical literature (PubMed and Google Scholar) and the EudraVigilance database of suspected adverse drug reaction reports were searched for case reports of false-positives with radiopharmaceuticals appearing in lactating breasts. Medical Dictionary for Regulatory Activities (MedDRA) was reviewed for terms that could be used to capture reports of false-positives occurring in breast nuclear imaging accurately.
Results: Literature searches showed that 40 case reports of false-positives have been observed with radiopharmaceuticals in lactating breasts but that these do not appear to be consistently reported to EudraVigilance as adverse events. MedDRA did not contain terms suitable for capturing false-positives in breasts with radiopharmaceuticals, but newly proposed terms were all approved.
Conclusion: Increased reporting of false-positives as adverse events could help further clarify the safety specification of radiopharmaceuticals.
Radiotracers; lactation; pharmacovigilance; adverse events; false-positives.
Copyright © 2020 by the author(s). Licensee Global Clinical and Translational Research. This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution License (CCBY4.0, https:// creative-commons.org /licenses /by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
How to cite this article:
Kisic V, Parish J. False-positive results of radionuclide imaging in lactating breasts: a pharmacovigilance perspective. Glob Clin Transl Res. 2020; 2 (2): 38-45. DOI:10.36316/gcatr.01.0029.
1. International Atomic Energy Agency. Human Health Campus - Nuclear Medicine [Internet]. [cited 2020 Mar 27]. Available from: https://humanhealth.iaea.org/HHW/NuclearMedicine/index.html.
2. Council Regulation (EC) 2008/104/EC of November 19, 2008 on the Community code relating to medicinal products for human use. Core EU Legis. 2015;426–9. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32001L0083&from=EN.
3. The Radiochemistry Society. Nuclear Medicine: Radiopharmaceuticals Definition [Internet]. [cited 2018 Dec 18]. Available from: http://www.radiochemistry.org/nuclearmedicine/radiopharm_define.shtml.
4. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). FDA Guidance for Industry. Developing Medical Imaging Drug and Biological Products. Part 1: Conducting Safety Assessments [Internet]. 2004. Available from: https://www.fda.gov/media/71212/download.
5. Mammě M, Citraro R, Torcasio G, Cusato G, Palleria C, di Paola ED. Pharmacovigilance in pharmaceutical companies: An overview. J Pharmacol Pharmacother. 2013 Dec; 4(Suppl1): S33–7. DOI:10.4103/0976-500X.120945.
6. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Multidisciplinary Guidelines M3 (R2) —Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceutical [Internet]. Available from: https://database.ich.org/sites/default/files/M3_R2__Guideline.pdf. Accessed on April 1, 2020.
7. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Multidisciplinary Guidelines E8 - General Considerations for Clinical Trials [Internet]. Available from: https://database.ich.org/sites/default/files/E8_Guideline.pdf. Accessed on April 1, 2020.
8. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013 Jun; 5 Suppl 1: S2-8. DOI: 10.3978/j.issn.2072-1439.2013.05.24.
9. Helwick C. PET Scans Not Recommended for Most Patients with Breast Cancer: Potential New Controversy in Breast Cancer Testing. Am Health and Drug Benefits 2010; 3(2):148. Available from: http://www.ahdbonline.com/issues/2010/march-april-2010-vol-3-no-2/93-article-93.
10. Shin KM, Kim HJ, Jung SJ, Lim HS, Lee SW, Cho SH, et al. Incidental Breast Lesions Identified by 18 F-FDG PET/CT: Which Clinical Variables Differentiate between Benign and Malignant Breast Lesions? J Breast Cancer. 2015; 18(1):73. DOI:10.4048/jbc.2015.18.1.73.
11. Dong A, Wang Y, Lu J, Zuo C. Spectrum of the Breast Lesions with Increased 18F-FDG Uptake on PET/CT: Clin Nucl Med. 2016 Jul;41(7):543–57. DOI:10.1097/RLU.0000000000001203
12. Bhattacharya A, Kamaleshwaran K, Mittal B, Gayana S. Unilateral breast uptake of Tc-99m pertechnetate in a patient with a cold nodule of the thyroid. World J Nucl Med. 2012; 11(2):79. DOI:10.4103/1450-1147.103423.
13. Tc 99m Sestamibi Drug Result Page. In: MICROMEDEX [database on the Internet]. Greenwood Village (CO): Truven Health Analytics; publication year . Available from: www.micromedexsolutions.com. Subscription required to view.
14. Gallium Citrate Ga 67 Drug Result Page. In: MICROMEDEX [database on the Internet]. Greenwood Village (CO): Truven Health Analytics; publication year . Available from: www.micromedexsolutions.com. Subscription required to view.
15. Hyatt HW, Zhang Y, Hood WR, Kavazis AN. Lactation has persistent effects on a mother's metabolism and mitochondrial function. Sci Rep. 2017 December 7;7(1):1–13. DOI:10.1038/s41598-017-17418-7
16. The European Medicines Agency. Guideline on core SmPC and the package leaflet for fludeoxyglucose [Internet]. 2012 [cited 2018 Dec 10]. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-core-summary-product-characteristics-package-leaflet-fludeoxyglucose-18f_en.pdf.
17. The European Medicines Agency. EU Individual Case Safety Report (ICSR)1 Implementation Guide. [Internet]. 2017. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-union-individual-case-safety-report-icsr-implementation-guide_en.pdf.
18. The European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) - Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2) [Internet]. 2017. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf.
19. MedDRA® Term Selection: Points to Consider ICH-Endorsed Guide for MedDRA Users [Internet]. [cited 2019 21 January]. Available from: http://www.mssotools.com/mssoweb/PTC/v211/000240_ts_ptc_r416.html.
20. The European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4) [Internet]. 2017. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf.
21. Ko KH, Jung HK, Jeon TJ. Diffuse Intense 18F-FDG Uptake at PET in Unilateral Breast Related to Breastfeeding Practice. Korean J Radiol. 2013; 14(3):400. DOI: 10.3348/kjr.2013.14.3.400
22. Hendler D, Stemmer SM. Uncommon Reason for High Fluorodeoxyglucose Positron Emission Tomography Uptake. J Clin Oncol. 2010 Nov 10; 28(32): e659–60. DOI: 10.1200/JCO.2010.29.5543
23. Sutter CW, Stadalnik RC. Noncardiac uptake of technetium-99m sestamibi: an updated gamut. Semin Nucl Med. 1996 Apr; 26(2):135–40. DOI: 10.1016/s0001-2998(96)80035-3
24. Ceyrat Q, Ziade C, Tlili G, Fernandez P, Meyer M. Galactocele, Pitfall for the Evaluation by 18F-FDG PET/CT: Clin Nucl Med. 2018 Jul;43(7): e237–8. DOI: 10.1097/RLU.0000000000002119
25. Abhyankar A, Joshi J, Basu S. FDG Uptake in Unilateral Breast Related to Breastfeeding Practice in a Patient of Pulmonary Hydatid Cyst: Clin Nucl Med. 2012 Jul;37(7):676–8. DOI: 10.1097/RLU.0b013e31824d210d.
26. Li T, Tian J, Wang H, Chen Z, Zhao C. Pitfalls in positron emission tomography/computed tomography imaging: causes and their classifications. Chin Med Sci J Chung-Kuo Hsueh Ko Hsueh Tsa Chih. 2009 Mar; 24(1):12–9. DOI: 10.1016/s1001-9294(09)60052-3.
27. Shor M, Dave N, Reddy M, Ali A. Asymmetric FDG uptake in a lactating breast. Clin Nucl Med. 2002 Jul; 27(7):536. DOI: 10.1097/00003072-200207000-00019
28. Yasuda S, Fujii H, Takahashi W, Takagi S, Ide M, Shohtsu A. Lactating breast exhibiting high F-18 FDG uptake. Clin Nucl Med. 1998 Nov; 23(11):767–8. DOI: 10.1097/00003072-199811000-00010
29. Jain S, Sharma P, Mukherjee A, Bal C, Kumar R. “Witch’s milk” and 99mTc-pertechnetate uptake in neonatal breast tissue: an uncommon but not unexpected finding. Clin Nucl Med. 2013 Jul; 38(7):586–7. DOI: 10.1097/RLU.0b013e318292aaba.
30. Grove N, Zheng M, Bristow RE, Eskander RN. Extensive Tattoos Mimicking Lymphatic Metastasis on Positron Emission Tomography Scan in a Patient with Cervical Cancer. Obstet Gynecol. 2015 Jul; 126(1):182–5. 30. DOI: 10.1097/AOG.0000000000000701.
31. Tanabe Y, Sugiura K, Fujii S, Sugihara S, Ogawa T. Unilateral intense breast accumulation of ga-67 resulting from breast feeding. Clin Nucl Med. 2005 Dec; 30(12):801–3. DOI: 10.1097/01.rlu.0000187514.99254.0e.
32. Gupta R, Tripathi M, Sahoo M, Nazar A, Agarwal K, Kumar K, et al. Asymmetrical F-18 Fluorodeoxyglucose uptake in the breasts: A dilemma solved by patient history. Indian J Nucl Med. 2016; 31(1):83. 32. DOI: 10.4103/0972-3919.172377.
33. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Draft Guideline on Clinical Evaluation of Diagnostic Agents [Internet]. 2008. Available from: https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-clinical-evaluation-diagnostic-agents_en.pdf33.
34. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev 2) [Internet]. 2017. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf34.
35. WebCR | MedDRA MSSO [Internet]. [Cited 2019 21 January]. Available from: https://mssotools.com/webcr.